[Prevention of serological conflict due to Rh factor incompatibility by administration of domestic anti-Rh (D) immunoglobulin].

M. Skorczynski,Z. Skrzypulec,R. Wawryk,H. Skałba,S. Polak

1968-12-01

Ginekologia Polska

Abstract:

What problem does this paper attempt to address?

Clinical Outcomes and Risk Factors of Coronary Artery Aneurysms after Successful Percutaneous Coronary Intervention and Drug-Eluting Stent Implantation for Chronic Total Occlusions

Xin Zhong,Hua Li,Chenguang Li,Nobel Zong,David Liem,X'avia Chan,Shuning Zhang,Youen Zhang,Xinggang Wang,Xing Wu,Wenbin Zhang,Kang Yao,Xuebo Liu,Lei Ge,Kai Hu,Juying Qian,Mario Deng,Junbo Ge

DOI: https://doi.org/10.1016/j.ijchv.2014.06.004

2014-01-01

Abstract:ObjectiveThe study aimed to analyze the risk factors and long-term outcomes associated with coronary artery aneurysms (CAAs) after successful percutaneous coronary intervention (PCI) and drug-eluting stent (DES) implantation in patients with CTOs.BackgroundThere are sporadic data available on post-procedure CAAs after transcatheter revascularization for CTOs.Methods and resultsA total of 141 patients with 149 CTOs who underwent successful CTO-PCI and DES implantation with angiographic follow-up from 2004 to 2010 were included. Patients were divided into CAA group and non-CAA group according to the presence of CAAs in the follow-up angiography. The independent predictors and major adverse cardiac events (MACEs) including cardiac death, myocardial infarction (MI) and target-vessel revascularization (TVR) were compared between two groups. The incidence of CAAs was 11.4% (17/149) after index procedure. Multivariate analysis showed that age (OR: 0.925, CI 0.873–0.980, P = 0.008), ostial occlusion (OR: 6.715, CI 1.473–30.610, P = 0.014), the parallel wire technique (OR: 6.167, CI 1.709–22.259, P = 0.005) and DES length (OR: 1.030, CI 1.002–1.058, P = 0.036) were the independent predictors of CAAs after successful CTO-PCI and DES implantation. MACEs were similar between two groups (adjusted hazard ratio 0.670; 95% CI 0.160–2.808; P = 0.584) during the 5-year follow-up.ConclusionsThe independent predictors of CAAs after successful CTO-PCI and DES implantation are age, ostial occlusion, the parallel wire technique and DES length. CAAs after index procedure are not frequently associated with adverse clinical events under dual antiplatelet therapy. Further large clinical studies are warranted to explore the clinical implications of patients with this distinct new entity.
The factors influencing revascularization in patients underwent coronary artery stent implantation

李俊,薛智敏,张文斌,傅国胜,周斌全

2015-01-01

Abstract:Objective To investigate the factors influencing revascularization in patients underwent coronary artery stent implantation. Methods 544 patients who underwent coronary artery stent implantation received coronary angiography one year later. The clinical data, stent type and coronary lesion features were analyzed. Logistic regression analysis was performed to determine influencing factors of revascularization. Results Non- target lesion revascularization was performed in 91 cases, target lesion revascularization in 53 cases, both target and non target lesion revascularization in 3 cases, and no revascularization in 397 cases. The proportions of paclitaxel eluting stent (32.1% vs 11.8%, P<0.01) and true bifurcation lesion (18.9% vs 6.5%, P<0.01) were significantly higher in target lesion revascularization group. Logistic regression analysis confirmed that Paclitaxel eluting stent (OR 3.78,95 %CI 1.94~ 7.35, P<0.01) and true bifurcation lesion (OR 3.73, 95% CI 1.64~ 8.47, P<0.01) were influencing factors of target lesion revascularization and old myocardial infarction(OR 1.916, 95%CI 1.02~3.61, P<0.05) was influencing factor of non- target lesion revascularization. Conclusion Paclitaxel eluting stent and true bifurcation lesion are relevant to target lesion revascularization. Old myocardial infarction is relevant to non- target lesion revascularization.
Incidence and Predictors of Definite Stent Thrombosis after Coronary Stent Implantation.

Zhang Quan-yu,Li Yi,Guan Shao-yi,Wang Xiao-zeng,Jing Quan-min,Ma Ying-Yan,Wang Geng,Wang Bin,Deng Jie,Han Ya-ling

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.09.005

2012-01-01

Abstract:Background Coronary stents are widely used in percutaneous coronary intervention (PCI) procedures. We aimed to explore the incidence, predictors and characteristics of stent thrombosis (ST) after coronary stent implantation in routine clinical practice.Methods From data of 18 063 consecutive patients who underwent successful stent implantation in Shenyang Northern Hospital from 2004 to 2010, we identified patients with definite ST (n=140) and control patients (n=280) matched on age, diagnosis, sex, current antiplatelet medication and stent type. The incidence, predictors and characteristics of ST after coronary stent implantation were investigated.Results The incidence of angiographically confirmed ST was 0.78% (140/18 063). The time distribution of ST was acute in 43 (30.7%), subacute in 50 (35.7%), and late in 47 (33.6%) patients. Binary Logistic regression analysis identified the angiotensin-converting enzyme inhibitor (ACEI) (odds ratio (OR)=0.472, 95% Cl: 0.276-0.807, P=0.006) and heparin (OR=0.477, 95% Cl: 0.278-0.819, P=0.007) were associated with an reduced risk of cumulative ST. Stent length (OR=1.042, 95% CI: 1.026-1.058, P<0.001), serum creatinine total (OR=1.020, 95% CI: 1.004-1.035, P=0.04), cholesterol (OR=1.267, 95% Cl: 1.021-1.573, P=0.032), glucose (OR=1.086, 95% Cl: 1.002-1.176, P=0.044), and platelet aggregation (OR=1.113, 95% CI: 1.075-1.154, P<0.001) were associated with an increased risk of cumulative ST.Conclusion ST is associated with longer stent length and higher level of total cholesterol, glucose and platelet aggregation. Chin Med J 2012;125(9):1547-1551
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Ioannis Iakovou,Thomas Schmidt,Erminio Bonizzoni,Lei Ge,Giuseppe M Sangiorgi,Goran Stankovic,Flavio Airoldi,Alaide Chieffo,Matteo Montorfano,Mauro Carlino,Iassen Michev,Nicola Corvaja,Carlo Briguori,Ulrich Gerckens,Eberhard Grube,Antonio Colombo

DOI: https://doi.org/10.1001/jama.293.17.2126

2005-01-01

Abstract:Context Traditionally, stent thrombosis has been regarded as a complication of percutaneous coronary interventions during the first 30 postprocedural days. However, delayed endothelialization associated with the implantation of drug-eluting stents may extend the risk of thrombosis beyond 30 days. Data are limited regarding the risks and the impact of this phenomenon outside clinical trials. Objective To evaluate the incidence, predictors, and clinical outcome of stent thrombosis after implantation of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Design, Setting, and Patients Prospective observational cohort study conducted at 1 academic hospital and 2 community hospitals in Germany and Italy. A total of 2229 consecutive patients underwent successful implantation of sirolimus-eluting (1062 patients, 1996 lesions, 2272 stents) or paclitaxel-eluting (1167 patients, 1801 lesions, 2223 Stents) stents between April 2002 and January 2004. Interventions implantation of a drug-eluting stent (sirolimus or paclitaxel). All patients were pretreated with ticlopidine or clopidogrel and aspirin. Aspirin was continued indefinitely and clopidogrel or. ticlopidine for at least 3 months after sirolimus-eluting and for at least 6 months after paclitaxel-eluting stent implantation. Main Outcome Measures Subacute thrombosis (from procedure end through 30 days), late thrombosis (>30 days), and cumulative stent thrombosis. Results At 9-month follow-up, 29 patients (1.3%) had stent thrombosis (9 [0.8%] with sirolimus and 20 [1.7%] with paclitaxel; P=.09). Fourteen patients had subacute thrombosis (0.6%) and 15 patients had late thrombosis (0.7%). Among these 29 patients, 13 died (case fatality rate, 45%). Independent predictors of stent thrombosis were premature antiplatelet therapy discontinuation (hazard ratio [HR], 89.78; 95% Cl, 29.90-269.60; P<.001), renal failure (HR, 6.49; 95% Cl, 2.60-16.15; P<.001), bifurcation lesions (HR, 6.42; 95% Cl, 2.93-14.07; P<.001), diabetes (HR, 3.71; 95% Cl, 1.74-7.89; P=.001), and a lower ejection fraction (HR, 1.09; 95% Cl, 1.05-1.36; P<.001 for each 10% decrease). Conclusions The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive "real-world" patients was substantially higher than the rate reported in clinical trials. Premature antiplatelet therapy discontinuation, renal failure, bifurcation lesions, diabetes, and low ejection fraction were identified as predictors of thrombotic events.
Markers of coagulation and early coronary stent thrombosis

L Galli,A Sator,S Schauer,K Braeu,J Bernhard,C Hengstenberg,C Gangl,I Lang,C Roth,R Berger,K Krychtiuk,W Speidl

DOI: https://doi.org/10.1093/eurheartj/ehae666.1495

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Acute stent thrombosis is a rare but deleterious event after percutaneous coronary intervention (PCI). Hemostatic factors such as D-Dimer, fibrinogen, and platelet count have emerged as potential indicators of increased thrombotic risk. However, data regarding the association with early stent thrombosis (ST) is sparse. Purpose The aim of this study was to investigate whether markers of coagulation are associated with increased risk of early (< 30 days after PCI) ST. Methods Within a prospective single-center registry, we retrospectively analyzed the association between pre-procedural platelet count, plasma levels of fibrinogen and D-Dimer with the occurrence of early ST within 30 days after PCI. Results We included 10,714 consecutive patients who underwent percutaneous coronary intervention (PCI) with implantation of drug-eluting stents (DES). Pre-procedural measurements of platelet count, fibrinogen and D-Dimer was available in 6,337, 6,155 and 956 patients, respectively. The number of definite early ST within 30 days was 58 (0.92 %). Pre-procedural platelet count (p<0.05) and plasma levels of fibrinogen (p<0.05) were significantly higher in patients with early ST as compared to patients without ST. Whereas D-Dimer was not associated with early ST, patients in the fifth quintile of platelet count had a significant increased risk for early ST (HR 2.43; 95% CI 1.43 - 4.14; p=0.001) as compared to patients in the lower four quintiles and patients in the fifth quintile of fibrinogen had a significant increased risk for early ST (HR 1.86; 95% CI 1.07 – 3.26; p<0.05) as compared to patients in the lower four quintiles. These associations were independent of clinical risk factors, the presence of acute coronary syndromes and the number of stents. Conclusions Pre-procedural platelet count and plasma levels of fibrinogen are associated with the risk of early ST in patients after implantation of DES. Device-level risk factors like stent-type or size and procedure-level risk factors like peri-interventional medication and complications during stent apposition are associated with ST. Platelet count and plasma levels of fibrinogen may be additional patient-level risk factors that have to be taken in account in the development of future personalized strategies to prevent these rare but deleterious complications.

cardiac & cardiovascular systems
Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

Wang Chong-hui,Fang Quan,Zhang Shu-yang,Shen Zhu-jun,Fan Zhong-jie,Jin Xiao-feng,Zeng Yong,Liu Zhen-yu,Xie Hong-zhi,Yang Ming

DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.2012.16.001

IF: 6.133

2012-01-01

Chinese Medical Journal

Abstract:Background The long-term safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) are unclear and controversial issues in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES versus BMS implantation.Methods A total of 191 patients with acute STEMI undergoing PCI from Jan. 2005 to Dec. 2007 were enrolled. Patients received DES (n=83) or BMS (n=108) implantation in the infarction related artery according to physician's discretion. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of death, myocardial infarction (MI), target vessel revascularization (TVR) and stent thrombosis. The difference of MACE was observed between DES and BMS groups.Results The clinical follow-up duration was 3 years ((41.7 +/- 16.1) months). MACE occurred in 20 patients during three years follow-up. Logistic regression analysis showed that the left ventricular ejection fraction (LVEF) was an independent predictor for MACE in the follow-up period (P=0.0301). There was no significant difference in all-cause mortality (3.61% vs. 7.41%, P=0.2647), the incidence of myocardial infarction (0 vs. 0.93%, P=0.379) and stent thrombosis (1.20% vs. 1.85%, P=0.727) between the DES group and BMS group. The incidence of MACE was significantly lower in the DES group compared to the BMS group (4.82% vs. 14.81%, P=0.0253). The rate of TVR was also lower in the DES group (0 vs. 5.56%, P=0.029). In the DES group, there was no significant difference in the incidence of MACE between sirolimus eluting stents (SES, n=73) and paclitaxel-eluting stents (PES, n=10) subgroups (2.74% vs. 20.00%, P>0.05).Conclusions This finding suggested that drug-eluting stents significantly reduced the need for revascularization in patients with acute STEMI, without increasing the incidence of death or myocardial infarction. Use of DES significantly decreased the incidence of MACE compared with BMS during the 3-year follow-up. Chin Med J 2012;125(16):2803-2806
LETTER: URACHAL HERNIA: AN UNUSUAL INTRA-ABDOMINAL HERNIA CAUSED BY INCARCERATION INTO A URACHAL CYST

T. Yamazaki,Y. Sakai,K. Hatakeyama,Y. Sekine,Y. Yuki

DOI: https://doi.org/10.1023/A:1005671832198

2000-12-01

Digestive Diseases and Sciences

Abstract:
Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges

Atsushi Sakamoto,Yu Sato,Rika Kawakami,Anne Cornelissen,Masayuki Mori,Kenji Kawai,Raquel Fernandez,Daniela Fuller,Neel Gadhoke,Liang Guo,Maria E. Romero,Frank D. Kolodgie,Renu Virmani,Aloke V. Finn

DOI: https://doi.org/10.1080/14779072.2021.1856657

2021-01-20

Expert Review of Cardiovascular Therapy

Abstract:Introduction: In-stent restenosis (ISR) has been one of the biggest limitations to the success of percutaneous coronary intervention for the treatment of coronary artery disease (CAD). The introduction of drug-eluting stent (DES) was a revolution in the treatment of CAD because these devices drastically reduced ISR to very low levels (<5%). Subsequently, newer generation DES treatments have overcome the drawbacks of first-generation DES, i.e. delayed endothelialization, and late stent thrombosis. However, the issue of late ISR, including neoatherosclerosis after DES implantation especially in high-risk patients and complex lesions, still exists as a challenge to be overcome. Areas covered: We discuss the mechanisms of ISR development including neoatherosclerosis, past and current clinical status of ISR, and methods to predict and overcome this issue from pathological and clinical points of view. Expert opinion: The initial drawbacks of first-generation DES, such as delayed endothelial healing and subsequent risk of late stent thrombosis, have been improved upon by the current generation DES. To achieve better long-term clinical outcomes, further titration of drug-release and polymer degradation profile, strut thickness as well as material innovation are needed.
Long-term Outcome Analysis of Patients Underwent Percutaneous Coronary Intervention with Prior Ischemic Stroke

Ye-chen Han,Shu-yang Zhang,Song-bai Lin,Zhu-jun Shen,Zhong-jie Fan,Chong-hui Wang,Xiao-feng Jin,Hong-zhi Xie,Zhen-yu Liu,Yong Zeng,Quan Fang

DOI: https://doi.org/10.3760/cma.j.issn.0253-3758.2011.11.002

2011-01-01

Abstract:OBJECTIVE:To analyze the clinical characteristics and long-term outcomes of patients underwent percutaneous coronary intervention (PCI) with prior ischemic stroke.METHODS:A total of 2053 patients underwent PCI in Peking union medical college hospital from January 2003 to December 2007 were included in this analysis and patients were followed up to December 2009. End-point included all-cause mortality, cardiac death, stent thrombosis, target-lesion revascularization, myocardial infarction, re-cerebral infarction. Major bleeding events were recorded during follow-up.RESULTS:There are 1945 coronary heart disease patients were followed up and 222 patients with prior ischemic stroke. Compared patients without prior ischemic stroke, patients with prior ischemic stroke were older (P = 0.000), had higher hypertension morbidity (P = 0.000), higher diabetes mellitus morbidity (P = 0.005), higher incidence of multi-vessels disease (P = 0.000). During the follow-up of (35.0 ± 19.6) months, cardiac death rate (8.5% vs. 3.9%, P = 0.002) and re-cerebral infarction rate (5.8% vs. 1.4%, P = 0.000) were higher in patients with prior ischemic stroke than patients without prior ischemic stroke. Dual antiplatelet therapy treatment time [(13.77 ± 11.33) months vs. (13.94 ± 11.33) months, P = 0.986] and major bleeding events (5.8% vs. 3.6%, P = 0.100) were similar between the two groups and cerebral hemorrhage rate (1.8% vs. 0.5%, P = 0.028) were higher in patients with prior ischemic stroke than patients without prior ischemic stroke.CONCLUSION:Patients with prior ischemic stroke were associated with increased rate of risk factors, multiple coronary artery disease, cardiac death and re-cerebral infarction and higher cerebral hemorrhage rate during follow-up despite similar dual-anti platelet therapy time.
Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up

Gong Cheng,Feng-jun Chang,Yi Wang,Peng-Hua You,Hai-chao Chen,Wen-qi Han,Jun-wei Wang,Ni-er Zhong,Zhi-qian Min

DOI: https://doi.org/10.12659/msm.908692

2019-01-08

Medical Science Monitor

Abstract:BACKGROUND This study observed the incidence of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) and discusses the risk factors of ISR based on clinical data, coronary angiography, and stent features, to provide a theoretical basis for the prevention and treatment of ISR. MATERIAL AND METHODS We selected 1132 cases who received stent implantation at the Shaanxi People's Hospital from June 2014 to June 2016 and were followed up by coronary angiography within 1 year. Based on coronary angiography, the cases were divided into ISR and non-ISR groups. ISR was defined as a reduction in lumen diameter by over 50% after PCI. The ISR group consisted of 93 cases and the non-ISR group consisted of 1039 cases. Medical history, biochemical indicators, features of coronary artery lesions, and stent status were analyzed retrospectively. Risk factors of ISR were identified by univariate and multivariate logistic regression analyses. RESULTS Among 1132 cases, 93 cases had ISR, with the overall incidence of 8.21%. Univariate and multivariate logistic regression analyses indicated that postoperative hypersensitive C-reactive protein (hs-CRP) levels (OR=2.309, 1.579-3.375 mg/L), postoperative homocysteine (HCY) levels (OR=2.202, 1.268-3.826 μmol/L), history of diabetes (OR=1.955,1.272-3.003), coronary bifurcation lesions (OR=3.785, 2.246-6.377), and stent length (OR=1.269, 1.179-1.365 mm) were independent risk factors of ISR after PCI (P<0.05). CONCLUSIONS Elevated hs-CRP and HCY levels after PCI, history of diabetes, coronary bifurcation lesions, and greater stent length were associated with a higher risk of ISR. Patients with a higher risk of ISR should receive routine follow-up and intense medication management after PCI to control the risk factors and to reduce ISR.

medicine, research & experimental
Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

Gerald Chi,Fahad AlKhalfan,Jane J. Lee,Sahar Memar Montazerin,Clara Fitzgerald,Serge Korjian,Wally Omar,Elliot Barnathan,Alexei Plotnikov,C. Michael Gibson

DOI: https://doi.org/10.3389/fcvm.2023.1269011

IF: 3.6

2024-01-09

Frontiers in Cardiovascular Medicine

Abstract:Background: Stent thrombosis (ST) is an uncommon but serious complication of stent implantation. This study aimed to explore factors associated with early, late, and very late ST to help guide risk assessment and clinical decision-making on ST. Methods: The analysis included patients who received stent placement for the index acute coronary syndrome (ACS). Cumulative incidence of ST was assessed at 30 days (early ST), 31–360 days (late ST), 361–720 days (very late ST), and up to 720 days. Cox proportional hazards models were used to assess associations between ST and various factors, including patient characteristics [i.e., age, sex, ACS presentation, history of hypertension, smoking, diabetes, prior myocardial infarction (MI), heart failure, prior ischemic stroke, and cancer], laboratory tests [i.e., positive cardiac biomarker, hemoglobin, platelet count, white blood cell (WBC) count], and treatment [i.e., drug-eluting stent (DES) vs. bare-metal stent (BMS) and anticoagulant with rivaroxaban vs. placebo]. Results: Among the 8,741 stented patients, 155 ST events (2.25%) occurred by Day 720. The cumulative incidences of early, late, and very late ST were 0.80%, 0.81%, and 0.77%, respectively. After multivariable adjustment, age ≥ 75 [hazard ratio (HR) = 2.13 (95% confidence interval, CI: 1.26–3.60)], a history of prior MI [HR = 1.81 (95% CI: 1.22–2.68)], low hemoglobin level [HR = 2.34 (95% CI: 1.59–3.44)], and high WBC count [HR = 1.58 (95% CI: 1.02–2.46)] were associated with a greater risk of overall ST, whereas DES [HR = 0.56 (95% CI: 0.38–0.83)] and rivaroxaban therapy [HR = 0.63 (95% CI: 0.44–0.88)] were associated with a lower risk of overall ST up to 720 days. Low hemoglobin level and high WBC count were associated with early ST (low hemoglobin: HR = 2.35 [95% CI: 1.34–4.12]; high WBC count: HR = 2.11 [95% CI: 1.17–3.81]). Low hemoglobin level and prior MI were associated with a greater risk of late ST (low hemoglobin: HR = 2.32 [95% CI: 1.26–4.27]; prior MI: HR = 2.98 [95% CI: 1.67–5.31]), whereas DES was associated with a lower risk of late ST [HR = 0.33 (95% CI: 0.16–0.67)]. Age ≥75 years was associated with very late ST. Conclusion: The study identified positive and negative associations with early, late, and very late ST. These variables may be useful in constructing risk assessment models for ST. Clinical Trial Registration: http://www.clinicaltrials.gov, identifier NCT00809965.

cardiac & cardiovascular systems
The Mechanisms of Restenosis and Relevance to Next Generation Stent Design

Jessie Clare,Justin Ganly,Christina A Bursill,Huseyin Sumer,Peter Kingshott,Judy B de Haan

DOI: https://doi.org/10.3390/biom12030430

IF: 6.064

2022-03-10

Biomolecules

Abstract:Stents are lifesaving mechanical devices that re-establish essential blood flow to the coronary circulation after significant vessel occlusion due to coronary vessel disease or thrombolytic blockade. Improvements in stent surface engineering over the last 20 years have seen significant reductions in complications arising due to restenosis and thrombosis. However, under certain conditions such as diabetes mellitus (DM), the incidence of stent-mediated complications remains 2-4-fold higher than seen in non-diabetic patients. The stents with the largest market share are designed to target the mechanisms behind neointimal hyperplasia (NIH) through anti-proliferative drugs that prevent the formation of a neointima by halting the cell cycle of vascular smooth muscle cells (VSMCs). Thrombosis is treated through dual anti-platelet therapy (DAPT), which is the continual use of aspirin and a P2Y12 inhibitor for 6-12 months. While the most common stents currently in use are reasonably effective at treating these complications, there is still significant room for improvement. Recently, inflammation and redox stress have been identified as major contributing factors that increase the risk of stent-related complications following percutaneous coronary intervention (PCI). The aim of this review is to examine the mechanisms behind inflammation and redox stress through the lens of PCI and its complications and to establish whether tailored targeting of these key mechanistic pathways offers improved outcomes for patients, particularly those where stent placement remains vulnerable to complications. In summary, our review highlights the most recent and promising research being undertaken in understanding the mechanisms of redox biology and inflammation in the context of stent design. We emphasize the benefits of a targeted mechanistic approach to decrease all-cause mortality, even in patients with diabetes.
Non-target lesion progression: Unveiling critical predictors and outcomes in patients with in-stent restenosis

Wei Zhang,Yi Deng,Ning Gu,Zhimei Qiu,Chancui Deng,Shuangya Yang,Li Pan,Shiwen Long,Yan Wang,Yongchao Zhao,Bei Shi

DOI: https://doi.org/10.1016/j.ijcard.2024.132451

2024-08-13

Abstract:Background: Percutaneous coronary intervention (PCI) has become the primary treatment for coronary artery disease. However, while PCI effectively addresses severe stenosis or occlusive lesions in target vessels, the progression of non-target vessel plaque remains a critical determinant of long-term patient prognosis. Aims: The purpose of this study was to investigate the impact of non-target vascular plaque progression on prognosis after PCI for ISR. Methods: This study included 195 patients diagnosed with ISR and multivessel disease who underwent successful PCI with drug-eluting stent (DES) placement, along with intraoperative optical coherence tomography (OCT) assessment of the culprit stent. Subsequent rechecked coronary angiography categorized eligible patients into non-target lesion progression (N-TLP) and no-N-TLP groups. We evaluated the baseline morphological characteristics of N-TLP by OCT and investigated the relationship between N-TLP, non-culprit vessel-related major adverse cardiovascular events (NCV-MACE), and pan-vascular disease-related clinical events (PVD-CE) incidence. Results: Multivariate logistic regression analysis revealed that diabetes mellitus (OR 3.616, 95% CI: 1.735-7.537; P = 0.001), uric acid level (OR 1.005, 95% CI: 1.001-1.009; P = 0.006), in-stent neoatherosclerosis (ISNA) (OR 1.334, 95% CI: 1.114-1.985; P = 0.047) and heterogeneous neointima morphology (OR 2.48, 95% CI: 1.18-5.43; P = 0.019) were independent predictors for N-TLP. Furthermore, N-TLP was associated with a high incidence of NCV-MACE (19.4% vs 6.9%, P = 0.009) and PVD-CE (83.9% [95% CI: 79.7%-88.3%] vs 93.1% [95% CI: 88.4%-98.0%], P = 0.038) after PCI in ISR patients. Conclusion: Diabetes, uric acid levels, ISNA, and heterogeneous neointima are predictive factors for subsequent rapid plaque progression, with N-TLP exacerbating the incidence of NCV-MACE and PVD-CE after PCI.
Analysis of influential factors of stent-related adverse events after percutaneous coronary intervention more than twice: a single-center retrospective study

Jing Li,Yu Liang,Pengfei Chen

DOI: https://doi.org/10.1038/s41598-024-79362-7

IF: 4.6

2024-11-14

Scientific Reports

Abstract:We aimed to assess the factors affecting patient outcomes in multiple stent placements over a 10-year period. The single-center study included 1,200 patients who had multiple stents implanted at least twice or more. Participants were divided into the adverse outcomes as endpoints ( n = 204 [17%]) and control groups. Univariate and multivariate analyses of stent-related adverse events risk during 10 years and logistic regression analysis of the adverse outcomes risk factors were performed. Univariate analysis revealed the impact of acute coronary syndrome (ACS), diabetes mellitus, hypertriglyceridemia, cumulative lesions in the left anterior descending (LAD) and left circumflex (LCX) arteries, number of stents in the LAD, LCX, and right coronary artery (RCA), presence of multiple coronary artery lesions, total number of stents used, and intervals between the first and second and between the fourth and fifth implantations. For secondary stent implantation, significant factors in univariate analysis included the number of LAD and LCX lesions, stents in LAD, LCX, and RCA, extent of coronary lesions, ACS, hypertension, diabetes, and total stent count. Many factors affect the outcomes in this patient group over time. Reducing the need for frequent percutaneous coronary intervention and considering the number of stents implanted are essential to improving outcomes.

multidisciplinary sciences
In-Stent Restenosis: Achilles’ Heel of Post-PCI Era

Sheng-Nan Zhou,Le Yang,Bi-Yang Feng,Lei Liu,Li-Ming Chen

DOI: https://doi.org/10.33696/cardiology.5.047

2024-01-05

Journal of Clinical Cardiology

Abstract:Despite advancements in stent design and polymer coatings over the past two decades, 1% to 2% of patients annually still experience instent restenosis (ISR). ISR reduces myocardial perfusion, may develop symptoms of myocardial ischemia, and thus leads to a high risk of myocardial infarction and cardiac death. Given that millions of drug-eluting stents (DES) are implanted globally every year, ISR remains a prevalent clinical issue with significant public health implications. Coronary intravascular imaging, includes intravascular ultrasound (IVUS) and optical coherence tomography (OCT), can help physicians gain deeper insights into the potential mechanisms of ISR. The preferred treatment strategy hinges on an accurate diagnosis and better understanding of etiology. The mechanism of ISR is multifaceted, and its treatment is challenging. Although the risk of ISR continues to decrease with advancements in DES application, further research is still needed to enrich the treatment options for ISR.
Clinical and Vessel Characteristics Associated with Hard Outcomes after PCI and Their Combined Prognostic Implications.

Seokhun Yang,Doyeon Hwang,Jinlong Zhang,Jiesuck Park,Jun Pil Yun,Joo Myung Lee,Chang-Wook Nam,Eun-Seok Shin,Joon-Hyung Doh,Shao-Liang Chen,Tsunekazu Kakuta,Gabor G. Toth,Zsolt Piroth,Nils P. Johnson,Abdul Hakeem,Barry F. Uretsky,Yohei Hokama,Nobuhiro Tanaka,Hong-Seok Lim,Tsuyoshi Ito,Akiko Matsuo,Lorenzo Azzalini,Massoud A. Leesar,Tara Neleman,Nicolas M. van Mieghem,Roberto Diletti,Joost Daemen,Damien Collison,Carlos Collet,Bernard De Bruyne,Bon-Kwon Koo

DOI: https://doi.org/10.1161/jaha.123.030572

2023-01-01

Abstract:BACKGROUND: Cardiac death or myocardial infarction still occurs in patients undergoing contemporary percutaneous coronary intervention (PCI). We aimed to identify adverse clinical and vessel characteristics related to hard outcomes after PCI and to investigate their individual and combined prognostic implications. METHODS AND RESULTS: From an individual patient data meta-analysis of 17 cohorts of patients who underwent post-PCI fractional flow reserve measurement after drug-eluting stent implantation, 2081 patients with available clinical and vessel characteristics were analyzed. The primary outcome was cardiac death or target-vessel myocardial infarction at 2 years. The mean age of patients was 64.2 +/- 10.2 years, and the mean angiographic percent diameter stenosis was 63.9%+/- 14.3%. Among 11 clinical and 8 vessel features, 4 adverse clinical characteristics (age >= 65 years, diabetes, chronic kidney disease, and left ventricular ejection fraction <50%) and 2 adverse vessel characteristics ( post-PCI fractional flow reserve <= 0.80 and total stent length >= 54 mm) were identified to independently predict the primary outcome (all P<0.05). The number of adverse vessel characteristics had additive predictability for the primary end point to that of adverse clinical characteristics (area under the curve 0.72 versus 0.78; P=0.03) and vice versa (area under the curve 0.68 versus 0.78; P=0.03). The cumulative event rate increased in the order of none, either, and both of adverse clinical characteristics >= 2 and adverse vessel characteristics >= 1 (0.3%, 2.4%, and 5.3%; P for trend <0.01). CONCLUSIONS: In patients undergoing drug-eluting stent implantation, adverse clinical and vessel characteristics were associated with the risk of cardiac death or target-rative assessment can optimize post-PCI risk stratification.
High platelet reactivity strongly predicts early stent thrombosis in patients with drug-eluting stent implantation

Subin Lim,Soon Jun Hong,Ju Hyeon Kim,Jung-Joon Cha,Hyung Joon Joo,Jae Hyoung Park,Cheol Woong Yu,Byeong-Keuk Kim,Kiyuk Chang,Yongwhi Park,Young Bin Song,Sung Gyun Ahn,Jung-Won Suh,Sang Yeub Lee,Jung Rae Cho,Ae-Young Her,Young-Hoon Jeong,Hyo-Soo Kim,Moo Hyun Kim,Eun-Seok Shin,Do-Sun Lim,Hyun Kuk Kim,Jung Hee Lee,Byoung Kwon Lee,Weon Kim,Kyung Woo Park,Jae Yeon Moon,Osung Kwon,Chan Joon Kim,Hyun-Woong Park,Chang Hoon Lee,Woo Jin Jang,Han-Young Jin,Min Ku Chon,Ki Hong Choi,Dong Hoon Han,Min Gyu Kang,Jeehoon Kang,You Jeong Ki,Jin Sup Park,Seung-Jun Lee,Seung Hun Lee,Jong-Young Lee,Sung Won Cho,Jon Suh,Jang-Whan Bae,Seng Chan You,Do-Sun Lim,Myung Ho Jeong,PTRG Investigators

DOI: https://doi.org/10.1038/s41598-023-50920-9

IF: 4.6

2024-01-05

Scientific Reports

Abstract:Stent thrombosis (ST) is a fatal complication after percutaneous coronary intervention (PCI). The association between P2Y12 reaction unit (PRU) level and stent thrombosis occurrence remains unclear. Based on the multicenter, observational PTRG-DES (Platelet function and genoType-Related long-term proGnosis in DES-treated patients) registry of patients with drug-eluting stents (DES) implantation, a total of 11,714 patients with PRU values were analyzed. We sought to identify the predictors of early stent thrombosis (EST) and compared the primary outcome, a composite of cardiac death, myocardial infarction, and revascularization, between EST and non-EST groups. EST, defined as definite ST within 1 month after index PCI, occurred in 51 patients. PRU values were significantly higher in the EST group (263.5 ± 70.8 vs. 217.5 ± 78.7, p < 0.001). In multivariable analysis, PRU ≥ 252 (OR, 5.10; 95% CI 1.58–16.46; p = 0.006) and aspirin reaction unit ≥ 414 (OR 4.85; 95% CI 1.07–21.97; p = 0.040) were independent predictors of EST. The cumulative incidence of primary composite outcome at one year was significantly higher in the EST group (38.2% vs. 3.9%, Log-rank p < 0.001). In patients treated with clopidogrel after successful DES implantation, EST was associated with higher platelet reactivities, and a greater risk of cardiovascular events.

multidisciplinary sciences
Analysis of Risk Factors for Early Stent Thrombosis in the Chinese Population: A Multicenter Restrospective Study.

Yu-peng Wang,Lei Ding,Rui-tao Zhang,Xiao-zeng Wang,Dan-qing Yu,Shou-yan Hao,Jin-wei Tian,Zhen-yu Liu,Xiang-qian Qi,Hu Tan,Hong-yi Wu,Feng-hua Ding,Li-jun Guo,Ya-ling Han

DOI: https://doi.org/10.5847/wjem.j.1920-8642.2021.03.005

2021-01-01

World Journal of Emergency Medicine

Abstract:BACKGROUND:The predictive scoring systems for early stent thrombosis (EST) remains blank in China. The study aims to evaluate the risk factors and conduct a prediction model of EST in the Chinese population.METHODS:EST was defined as thrombosis that occurs within the first 30 days after primary percutaneous coronary intervention (PCI). Patients from ten Chinese hospitals diagnosed as stent thrombosis (ST) from January 2010 to December 2016 were retrospectively included as the study group. A control group (1 case:2 controls) was created by including patients without ST, major adverse cardiovascular events, or cerebrovascular events during follow-up. The present study evaluated 426 patients with single-vessel lesions and ultimately included 40 patients with EST and 80 control patients, who were included to identify factors that predicted EST and to develop a prediction scoring system. The other 171 patients without integrated 1:2 pair were used for external validation.RESULTS:EST was independently associated with a low hemoglobin concentration (adjusted odds ratio [OR] 0.946, 95% confidence interval [95% CI] 0.901-0.993, P=0.026), a high pre-PCI Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score (OR 1.166, 95% CI 1.049-1.297, P=0.004), and a DAPT (DAPT) duration of <30 days (OR 28.033, 95% CI 5.302-272.834, P<0.001). The simple EST prediction score provided an area under the curve (AUC) of 0.854 (95% CI 0.777-0.932, P<0.001) with 70.0% sensitivity and 90.0% specificity, and 0.742 (95% CI 0.649-0.835, P<0.001) with 54.5% sensitivity and 81.0% specificity for external validation dataset.CONCLUSIONS:EST may be independently associated with DAPT discontinuation within 30 days, a low hemoglobin concentration, and a high SYNTAX score. The scoring system also has a good ability to predict the risk of EST and may be useful in the clinical setting.
Drug-Eluting Stent and Late Stent Thrombosis

LIU Jian,WANG Wei-min

DOI: https://doi.org/10.3969/j.issn.1004-3934.2007.04.003

2007-01-01

Abstract:Coronary stents are widely used during percutaneous coronary intervention procedures nowadays. Stent thrombosis,a complication of both bare-metal stents(BMS) and drug-eluting stents(DES),is associated with high rates of myocardial infarction and death. Recently,the advent of DES has raised concerns regarding later occurrence of stent thrombosis,whereas other data suggest an absent of such a risk. Several factors are associated with an increased risk of stent thrombosis,including the procedure itself,patient and lesion characteristics,stent design,and premature cessation of antiplatelet drugs.
Clinical Characteristics of Early and Late Drug-Eluting Stent In-Stent Restenosis and Mid-Term Prognosis after Repeated Percutaneous Coronary Intervention.

Jian-Feng Zheng,Ting-Ting Guo,Yuan Tian,Yong Wang,Xiao-Ying Hu,Yue Chang,Hong Qiu,Ke-Fei Dou,Yi-Da Tang,Jin-Qing Yuan,Yong-Jian Wu,Hong-Bing Yan,Shu-Bin Qiao,Bo Xu,Yue-Jin Yang,Run-Lin Gao

DOI: https://doi.org/10.1097/cm9.0000000000001135

2020-01-01

Abstract:Abstract. Background:. The mechanism and characteristics of early and late drug-eluting stent in-stent restenosis (DES-ISR) have not been fully clarified. Whether there are different outcomes among those patients being irrespective of their repeated treatments remain a knowledge gap. Methods:. A total of 250 patients who underwent initial stent implantation in our hospital, and then were readmitted to receive treatment for the reason of recurrent significant DES-ISR in 2016 were involved. The patients were categorized as early ISR (<12 months; E-ISR; n = 32) and late ISR (≥12 months; L-ISR; n = 218). Associations between patient characteristics and clinical performance, as well as clinical outcomes after a repeated percutaneous coronary intervention (PCI) were evaluated. Primary composite endpoint of major adverse cardiac events (MACEs) included cardiac death, non-fatal myocardial infarction (MI), or target lesion revascularization (TLR). Results:. Most baseline characteristics are similar in both groups, except for the period of ISR, initial pre-procedure thrombolysis in myocardial infarction, and some serum biochemical indicators. The incidence of MACE (37.5% vs. 5.5%; P < 0.001) and TLR (37.5% vs. 5.0%; P < 0.001) is higher in the E-ISR group. After multivariate analysis, E-ISR (odds ratio [OR], 13.267; [95% CI 4.984–35.311]; P < 0.001) and left ventricular systolic dysfunction (odds ratio [OR], 6.317; [95% CI 1.145–34.843]; P = 0.034) are the independent predictors for MACE among DES-ISR patients in the mid-term follow-up of 12 months. Conclusions:. Early ISR and left ventricular systolic dysfunction are associated with MACE during the mid-term follow-up period for DES-ISR patients. The results may benefit the risk stratification and secondary prevention for DES-ISR patients in clinical practice.

[Prevention of serological conflict due to Rh factor incompatibility by administration of domestic anti-Rh (D) immunoglobulin].

Clinical Outcomes and Risk Factors of Coronary Artery Aneurysms after Successful Percutaneous Coronary Intervention and Drug-Eluting Stent Implantation for Chronic Total Occlusions

The factors influencing revascularization in patients underwent coronary artery stent implantation

Incidence and Predictors of Definite Stent Thrombosis after Coronary Stent Implantation.

Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Markers of coagulation and early coronary stent thrombosis

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

LETTER: URACHAL HERNIA: AN UNUSUAL INTRA-ABDOMINAL HERNIA CAUSED BY INCARCERATION INTO A URACHAL CYST

Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents: current clinical approaches and challenges

Long-term Outcome Analysis of Patients Underwent Percutaneous Coronary Intervention with Prior Ischemic Stroke

Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up

Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial

The Mechanisms of Restenosis and Relevance to Next Generation Stent Design

Non-target lesion progression: Unveiling critical predictors and outcomes in patients with in-stent restenosis

Analysis of influential factors of stent-related adverse events after percutaneous coronary intervention more than twice: a single-center retrospective study

In-Stent Restenosis: Achilles’ Heel of Post-PCI Era

Clinical and Vessel Characteristics Associated with Hard Outcomes after PCI and Their Combined Prognostic Implications.

High platelet reactivity strongly predicts early stent thrombosis in patients with drug-eluting stent implantation

Analysis of Risk Factors for Early Stent Thrombosis in the Chinese Population: A Multicenter Restrospective Study.

Drug-Eluting Stent and Late Stent Thrombosis

Clinical Characteristics of Early and Late Drug-Eluting Stent In-Stent Restenosis and Mid-Term Prognosis after Repeated Percutaneous Coronary Intervention.